Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Ophthalmology, The Jingzhou Aier Eye Hospital, Jingzhou, China.
Ophthalmic Res. 2021;64(2):192-204. doi: 10.1159/000508738. Epub 2020 May 19.
Age-related macular degeneration (AMD) causes irreversible vision loss, and targeted anti-vascular endothelial growth factor (VEGF) therapy is now the most common and effective treatment. The aim of this meta-analysis is to discuss whether genetic polymorphism of ARMS2 A69S could confer susceptibility to advanced AMD with the response to anti-VEGF treatment. We performed a meta-analysis of relevant published studies selected through electronic databases. A total of 21 preferred studies regarding the association between ARMS2 gene and anti-VEGF treatment response in advanced AMD were generally included in the meta-analysis. The pooled results demonstrated that the carriage of G allele for ARMS2 A69S presented a better clinical prognosis for advanced AMD treated with anti-VEGF drugs (OR = 1.38, 95% CI = 1.13-1.69, p = 0.002). In addition, in the subgroup analysis based on ethnicity, ARMS2 polymorphisms were more likely to be a positive responder for East Asian patients (OR = 1.67, 95% CI = 1.29-2.16, p < 0.001). This meta-analysis through a series of rigorous methodology data demonstrated a significant association between ARMS2 A69S polymorphism and the anti-VEGF treatment response in advanced AMD, especially among East Asian population. Numerous well-designed, randomized, multicenter clinical trials with large sample size are required to validate the association.
年龄相关性黄斑变性（AMD）可导致不可逆转的视力丧失，而靶向抗血管内皮生长因子（VEGF）治疗目前是最常见和有效的治疗方法。本荟萃分析旨在探讨 ARMS2 A69S 基因多态性是否与抗 VEGF 治疗的晚期 AMD 易感性相关。我们通过电子数据库进行了相关已发表研究的荟萃分析。共有 21 项关于 ARMS2 基因与晚期 AMD 抗 VEGF 治疗反应之间关系的研究被普遍纳入荟萃分析。汇总结果表明，ARMS2 A69S 的 G 等位基因携带与抗 VEGF 药物治疗晚期 AMD 具有更好的临床预后（OR = 1.38，95% CI = 1.13-1.69，p = 0.002）。此外，基于种族的亚组分析表明，ARMS2 多态性更可能使东亚患者成为抗 VEGF 药物的阳性反应者（OR = 1.67，95% CI = 1.29-2.16，p < 0.001）。本荟萃分析通过一系列严格的方法学数据表明，ARMS2 A69S 多态性与晚期 AMD 的抗 VEGF 治疗反应之间存在显著关联，尤其是在东亚人群中。需要进行大量设计良好、随机、多中心的临床试验来验证这种关联。
